UK conditionally approves new treatment for HER2 positive breast cancer
The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a…
The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results.